Experienced in Systemic Sclerosis (SSc)

Dr. James H. Tarver

Cardiology
Florida Hospital Medical Group Inc
631 E Altamonte Dr, Suite 231, 
Altamonte Springs, FL 
Accepting New Patients
Offers Telehealth
Experienced in Systemic Sclerosis (SSc)
Florida Hospital Medical Group Inc
631 E Altamonte Dr, Suite 231, 
Altamonte Springs, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Tarver is a Cardiologist in Altamonte Springs, Florida. Dr. Tarver is rated as an Experienced provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Hypertension, and Systemic Sclerosis (SSc). Dr. Tarver is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Cardiology
Licenses
Internal Medicine in FL
Hospital Affiliations
Adventhealth Orlando
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

FLORIDA HOSPITAL MEDICAL GROUP INC
631 E Altamonte Dr, Suite 231, Altamonte Springs, FL 32701
Other Locations
FLORIDA HOSPITAL MEDICAL GROUP INC
2600 Westhall Ln, Maitland, FL 32751
FLORIDA HOSPITAL MEDICAL GROUP INC
601 E Rollins St, Orlando, FL 32803
FLORIDA HOSPITAL MEDICAL GROUP INC
2501 N Orange Ave, Orlando, FL 32804

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 07, 2023
Intervention Type: Drug
Study Drug: Intravenous/Subcutaneous Treprostinil
Study Phase: Phase 4
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

6 Total Publications

Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study.
Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study.
Journal: BMJ open respiratory research
Published: October 06, 2023
Similar Doctors
Experienced in Systemic Sclerosis (SSc)
Dr. Philip S. Owen
Interventional Cardiology | Cardiology
Experienced in Systemic Sclerosis (SSc)
Dr. Philip S. Owen
Interventional Cardiology | Cardiology

Lakeland Regional Health Systems Inc

3525 Lakeland Hills Blvd, 
Lakeland, FL 
 (53.1 miles away)
863-603-6565
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Philip Owen is an Interventional Cardiologist and a Cardiologist in Lakeland, Florida. Dr. Owen is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Angina, Coronary Heart Disease, Atherosclerosis, and Arterial Embolism. Dr. Owen is currently accepting new patients.

Experienced in Systemic Sclerosis (SSc)
Dr. Daniel R. Wubneh
Cardiology
Experienced in Systemic Sclerosis (SSc)
Dr. Daniel R. Wubneh
Cardiology

Florida Hospital Medical Group Inc

601 E Rollins St, 
Orlando, FL 
 (6.2 miles away)
407-303-2570
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Wubneh is a Cardiologist in Orlando, Florida. Dr. Wubneh is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Atrial Fibrillation, Fainting, Angina, and Pulmonary Veno-Occlusive Disease. Dr. Wubneh is currently accepting new patients.

Experienced in Systemic Sclerosis (SSc)
Dr. Mayuri H. Patel
Interventional Cardiology | Cardiology
Experienced in Systemic Sclerosis (SSc)
Dr. Mayuri H. Patel
Interventional Cardiology | Cardiology

Lakeland Regional Health Systems Inc

130 Pablo St, 
Lakeland, FL 
 (57.5 miles away)
863-284-5941
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients

Mayuri Patel is an Interventional Cardiologist and a Cardiologist in Lakeland, Florida. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). Her top areas of expertise are Heart Attack, Apoplexy, Angina, Angioplasty, and Pacemaker Implantation. Dr. Patel is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tarver's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile